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 Lysophosphatidylcholine (LPC) is a bioactive phospho-
lipid generated primarily by the action of phospholipase 
A2 (PLA2) enzymes on plasma membrane- and lipopro-
tein-phosphatidylcholine (PC) containing saturated fatty 
acid (FA) at the sn-1 and mostly unsaturated FA at the sn-2 
position ( 1–3 ). LPC can also be produced as a by-product 
by lecithin cholesterol acyltransferase (LCAT) in high-
density lipoprotein (HDL) ( 4 ) as well as from oxidation 
of low-density lipoprotein (LDL) ( 5 ) and by endothelial 
lipase (EL). 
 The physiological concentrations of LPC in body fl uids 
is high, around 150 µM ( 6, 7 ), with even millimolar levels 
in hyperlipidemic subjects ( 8 ). LPC in plasma is distrib-
uted between albumin or some other carrier serum pro-
teins ( 9, 10 ) and lipoproteins ( 11 ), with the likely existence 
of minute amounts of free LPC. This free LPC may tran-
siently arise during an excessive lipolysis when the concen-
trations of FA and LPC locally exceed the binding capacity 
of albumin. Under such conditions, LPC partitions tran-
siently to lipoproteins, from where it is rapidly delivered to 
cells. After uptake into cells, free LPC may be reacylated to 
yield PC ( 12 ) or deacylated to provide FA and choline 
( 10 ). Despite abundant evidence for the capacity of the 
free LPC to increase cytosolic Ca 2+ ( 13–16 ) and activate 
numerous signaling pathways ( 17, 18 ) resulting in an en-
hanced expression of infl ammatory molecules ( 19, 20 ) 
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 Cell culture 
 Human primary aortic endothelial cells (HAEC) were ob-
tained from Lonza and maintained in endothelial cell growth 
medium [EGM-MV Bullet Kit = EBM medium + growth supple-
ments + FCS (Lonza)] supplemented with 50 IU/ml penicillin 
and 50 µg/ml streptomycin. Cells were cultured in gelatin coated 
dishes at 37°C in a 5% CO 2 humidifi ed atmosphere and were 
used for experiments from passage 5 to 10. Cells were seeded 
(75000/well) in 12-well plates 48 h before exposure to LPC. 
 LPC treatment of HAEC 
 Initial time- and concentration-dependent experiments re-
vealed that in a serum-free medium in the absence of BSA, all 
tested LPC at concentrations up to 10 µM were not toxic to HAEC 
(for incubations up to 8 h), as determined by monitoring the 
release of lactate dehydrogenase (LDH) using the cytotoxicity 
detection kit (LDH) (Roche, Mannheim, Germany). 
 At 48 h after plating, cells were washed with PBS and incu-
bated with EBM medium without supplements and serum for 3 h. 
This medium is referred to as “serum-free medium” throughout 
the article. Thereafter, medium was removed and replaced with 
fresh serum-free medium supplemented with different concen-
trations of LPC alone or in some experiments along with AA 
or A23187. In some experiments, as indicated in the respective 
fi gure legends, LPC was applied in complex with BSA at a molar 
ratio of 1:1 and 5:1, respectively. Medium was collected in pre-
chilled tubes at different time points following exposure to LPC, 
spun to remove cells, and used for lactate dehydrogenase (LDH) 
assay and measurement of prostanoids. Cells were washed with 
PBS and lysed in respective buffers for isolation of RNA or 
proteins. 
 Pharmacological inhibitors 
 During fi nal 30 min of incubation with serum-free medium 
prior to exposure to LPC as well as during exposure to LPC, 
HAEC were treated with respective pharmacological inhibitors 
(all from Calbiochem) or vehicle (DMSO). Specifi c COX-1 in-
hibitor SC-560 (100 nM), COX-2 inhibitor NS-398 (20 µM), and 
cPLA2 inhibitor (1 µM) [(N-{(2S,4R)-4-(biphenyl-2-ylmethyl-
isobutyl-amino)-1-[2-(2,4-difl uorobenzoyl)-benzoyl]pyrrolidin-
2-ylmethyl}-3-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)-phenyl]
acrylamide, HCl)] were applied. 
 Quantitative real-time PCR 
 RNA of cell extracts was isolated using the peqGOLD Total 
RNA Kit (Peqlab-biotechnology, Erlangen, Germany) according 
to the manufacturer’s protocol, including on column DNase 
digestion. Then 1.5 µg of RNA were reverse transcribed using the 
Archive cDNA Kit (Applied Biosystems, Foster City, CA) and 0.7 
U of an RNase Inhibitor (Qiagen, Hilden, Germany). RT-PCR 
analysis was performed in 384-well plates in a total volume of 4 µl 
containing 2 ng of original total RNA using the QantiFast SYBR 
green RT-PCR kit (Qiagen) and validated QuantiTect Primer 
Assays (Qiagen) according to the manufacturer’s instructions 
for Light Cycler 480 instruments (Roche Diagnostics). In brief, 
after the initial heat activation step at 95°C for 5 min, cycling 
conditions consisted of 40 cycles of denaturation at 95°C for 10 s 
and combined annealing and extension at 60°C for 30 s. The 
PCR effi ciency of the target and housekeeping genes was deter-
mined by cDNA dilution series prepared from an untreated sam-
ple, and results were accordingly effi ciency-corrected with the 
LightCycler Relative Quantifi cation software (Roche Diagnostics, 
Basel, Switzerland). mRNA levels of COX-1 and COX-2 (Primer 
Assays QT00210280 and QT00040586) were normalized to human 
  -2-microglobulin (Primer Assay QT01665006) and expressed as 
and prostanoids (EC) ( 14, 21, 22 ), the role of the putative 
LPC receptors is still a matter of debate. 
 It is largely accepted that LPC may act via a subset of 
G protein-coupled receptors (GPCR), including GPR4, 
G2A (G2 accumulation), OGR1 (ovarian cancer G protein-
coupled receptor 1), and TDAG8 (T cell death-associated 
gene 8), that are sensitive to both LPC and protons 
( 23, 24 ). Of these receptors, GPR4 shows the widest tis-
sue distribution and is abundantly expressed in vascular 
endothelial cells where its expression is enhanced by in-
fl ammation ( 25 ). In contrast, G2A, whose cell surface 
expression and stabilization are enhanced by LPC ( 26 ) 
but whose proton-induced actions are antagonized by 
LPC ( 27 ), is mainly expressed in lymphoid tissue, lym-
phocytes, and macrophages ( 24 ). Although the initial papers 
were retracted due to failure to reproduce the binding 
of LPC to GPR4 and G2A, respectively, several studies 
have shown that LPC stimulates a variety of cellular activ-
ities dependent on GPR4 ( 25, 28, 29 ). However, some 
studies that failed to observe the LPC actions in GPR4-
expressing cells provided evidence for the capacity of 
GPR4 to sense extracellular protons, resulting in G-protein-
mediated intracellular signaling and cAMP accumula-
tion ( 30-32 ). 
 Prostanoid biosynthesis involves oxidation and subse-
quent isomerization of unesterifi ed arachidonic acid (AA). 
The initial step of this metabolic pathway is the stimulus-
induced release of AA from membrane phospholipids 
by phospholipase A2 (PLA2) enzymes, principally Ca 2+ -
dependent cytosolic PLA2IVA (cPLA2), followed by conver-
sion to prostaglandin H 2 (PGH 2 ) by either cyclooxygenase 
(COX)-1 or COX-2, both constitutively expressed by vascu-
lar endothelial cells (EC) ( 33–35 ). PGH 2 is then converted 
to various prostanoids by the respective terminal pros-
tanoid synthases ( 36, 37 ). 
 Endothelial lipase is a phospholipase localized on the 
surface of vascular endothelial cells ( 38, 39 ). We demon-
strated previously that EL, by cleaving HDL-PC, generates 
substantial amounts of LPC 16:0, 18:1, 18:2, and 20:4, re-
spectively ( 40 ). As studies investigating the impact of LPC 
on prostanoid production have so far used 16:0 LPC exclu-
sively ( 1, 14, 21, 22 ), nothing is known about the impact of 
the length and degree of saturation of the LPC-acyl chain 
on prostanoid production. Therefore, the aim of the pres-
ent study was to assess the impact of those LPC, found to 
be abundantly generated by EL, on PGI 2 production in 
vitro in HAEC and in vivo in mice. 
 MATERIALS AND METHODS 
 LPC 
 All LPC was purchased from Avanti Polar Lipids, and addi-
tional preparations of 18:2 and 20:4 were generated as de-
scribed elsewhere ( 41 ). LPC was dissolved and stored at   20°C 
in chloroform/methanol under argon atmosphere. For exper-
iments, required amounts of LPC were dried under a stream 
of nitrogen or argon and redissolved in PBS (pH 7.4) for cell 
culture experiments or in pyrogen-free saline for in vivo 
experiments. 
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goat anti-COX-2 (Santa Cruz Biotechnology, M19, sc-1747, 1:100) 
and the HRP-labeled rabbit anti-goat IgG (Dako) as a secondary 
antibody. Protein signals were detected by ECL assay, and the 
intensity was normalized to actin (Pierce, ms Anti-Actin IgM: 
1:4000) using densitometry. 
 Measurements of [Ca 2+ ] i 
 HAEC were seeded in 6-well plates. At 48 h after plating, 
cells were serum starved for 2 h and then loaded with 2 µM 
fura-2/AM for 60 min. After washing, cells were trypsinized 
and resuspended either in calcium buffer (138 mM NaCl, 1 
mM MgCl 2 , 5 mM KCl, 10 mM Hepes, 10 mM Glucose, pH 7.4) 
or EGTA buffer (0.1 mM EGTA, 138 mM NaCl, 1 mM MgCl 2 , 
5 mM KCl, 10 mM Hepes, 10 mM Glucose, pH 7.4). The ratio 
of fura-2 fl uorescence intensity at the two excitation wave-
lengths (340/380 ratio) was monitored spectrophotometri-
cally in a stirring cuvette before and after the injection of 10 µM 
LPC. In some experiments, cells were resuspended in EGTA 
buffer followed by a preincubation with either 100 µM 2-APB 
for 2 min or with 2 µM U73122 for 5 min before the injection 
of LPC. 
 Experiments in mice 
 Following a 6 h fasting period, 10–12-weeks-old male C57Bl/6J 
mice (4–7 per group) were treated with 20 mg/kg LPC in 0.9% 
NaCl (or NaCl alone) via tail vein injection. After 20 h, blood 
was collected from the retro-orbital plexus into tubes contain-
ing indomethacin and EDTA, centrifuged immediately, and 
stored at   70°C for measurements of 6-keto PGF 1   . For tail-
vein injection and bleeding, mice were anesthetized with Isofl u-
rane (Pharmacia and Upjohn SA, Guyancourt, France). Animal 
experiments were conducted in conformity with the Public 
Health Service Policy on Human Care and Use of Laboratory 
Animals and were approved by the Austrian Ministry of Science 
and Research according to the Regulations for Animal 
Experimentation. 
 Statistical analysis 
 Cell culture experiments were performed at least three times 
and values are expressed as mean plus SEM. Statistical signifi -
cance was determined by the Student’s unpaired  t -test (two-
tailed) with application of Welch´s correction, where required. 
Group differences were considered signifi cant for  P < 0.05 (*), 
 P < 0.01 (**), and  P < 0.001 (***). 
 RESULTS 
 LPC induces PGI 2 production in HAEC 
 As determined by GC-MS/MS analysis, HAEC secrete 
6-keto PGF 1   (a stable degradation product of PGI 2 ), 
thromboxane B 2 (TxB 2 ; a stable degradation product of 
TxA 2 ), PGF 2   , and PGE 2 ( Fig. 1A ). 
 To examine the impact of LPC on endothelial PGI 2 pro-
duction, HAEC were incubated with 10 µM LPC followed 
by EIA-based quantifi cation of 6-keto PGF 1   . As shown in 
 Fig. 1B , 16:0 LPC increased slightly (1.4-fold) and not sta-
tistically signifi cantly the formation of 6-keto PGF 1   rela-
tive to the PBS control. The increases in 6-keto PGF 1   
elicited by 18:1 LPC and 20:4 LPC were much more pro-
nounced at 3- and 8.3-fold, respectively. 18:2 LPC did not 
have any impact on 6-keto PGF 1   production (supplemen-
tary Fig. I) and was not further studied. 
relative ratio (   Ct). All samples were assayed in duplicate, and 
the average value was used for quantifi cation. 
 Prostanoid profi ling by GC-MS/MS 
 The spectrum of prostanoids produced by HAEC under 
basal conditions was determined by gas chromatography-
tandem mass spectrometry (GC-MS/MS) as described previously 
( 42 ). In brief, 10 µl deuterated internal standard mixture 
(about 1 ng of each PG) was added to 0.2–1 ml of each sample. 
After acidifi cation with formic acid (5%, v/v) to pH 2.6, a solu-
tion of 0.1 g methoxyamine hydrochloride in 1 ml sodium ac-
etate (1.5 M, pH 5.0) was added. The prostanoid derivates were 
extracted with ethyl acetate/hexane (7:3, v/v). After evapora-
tion, the residues were esterifi ed with a reaction mixture of ac-
etone (80 µl), diisopropylamine (7 µl), and pentafl uorobenzyl 
bromide (6 µl) for 10 min at 40°C. Dried samples were then 
applied to TLC and developed in ethyl acetate/hexane (9:1, 
v/v). The target zones were scraped off (Rf = 0.03–0.39) and 
extracted with ethyl acetate. The extracts were then evapo-
rated, derivatized twice with 10 µl BSTFA at 60°C, and analyzed 
using GC-MS/MS. 
 6-keto PGF 1   measurements by EIA 
 6-keto PGF 1   was measured in cell culture media and 5-fold 
diluted mouse plasma by a correlate-EIA kit (Cayman, Ann 
Arbor, MI) according to the manufacturer’s protocol. Protein 
content of cell culture wells was initially determined to be equal 
for all treatments. 
 14 C-Arachidonic acid and  14 C-6-keto PGF1  release 
 Cells were labeled with  14 C-AA (4 µM, spec. activity 58 mCi/
mmol) in complete medium for 20 h. Unbound  14 C-AA was re-
moved by excessive washing in PBS supplemented with 1% BSA. 
After incubation in serum-free medium for 3 h, and facultative 
preincubation with 1 µM cPLA2 inhibitor for 30 min, cells were 
exposed to 50 µM LPC + 3.7 µM BSA (± cPLA2 inhibitor) for 20 
min. Cell media were then collected, spun to remove cells, and 
immediately frozen at   70°C until extraction. Cells were washed 
with PBS and lysed in 0.3 M NaOH/0.1% SDS. Aliquots of the 
cell lysates were mixed with scintillation cocktail, and the radio-
activity was determined on a   -counter (Beckman). Acidifi ed 
media were extracted with 2 vol of hexane/isopropanol (3:2, 
v/v), evaporated in the SpeedVac, and redissolved in chloro-
form, followed by TLC using ethylacetate/isooctane/water/
acetic acid (11:5:10:2, v/v) as a mobile phase. The signals cor-
responding to  14 C-AA and  14 C-6-keto PGF1  were visualized 
upon exposure of the TLC plates to a tritium screen (GE 
Healthcare) on the STORM imager. Quantifi cation was per-
formed by densitometric volume report analysis or by liquid 
scintillation counting of cut out TLC spots corresponding to 
the comigrating AA- and 6-keto PGF1  -standard [visualized by 
spraying with primulin (0.01%, w/v) in acetone/water (60:40, 
v/v) and subsequent UV detection]. The amounts of  14 C-AA 
and  14 C-6-keto PGF1  released into medium were normalized 
to total cellular radioactivity measured by scintillation counting 
of cell lysates. 
 Western blotting 
 For quantifi cation of COX-2 protein, three 12-well plates of 
HAEC treated with LPC or PBS were washed with PBS and lysed 
in 50 µl of loading buffer [20% (w/v) glycerol, 5% (w/v) SDS, 
0.15% (w/v) bromophenol blue, 63 mmol/l Tris-HCl (pH 6.8), 
and 5% (v/v)   -mercaptoethanol] and boiled for 10 min. Then 
40 µl of the lysate were subjected to each lane and analyzed by 
SDS-PAGE (10% gel) and subsequent immunoblotting using 
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16:0 LPC, 2-fold by 18:1 LPC, and 1.6-fold by 20:4 LPC, 
upon 1 h incubation with 10 µM of LPC under our stan-
dard conditions (i.e., in serum-free medium without ad-
dition of NEFA-free BSA) ( Fig. 2B ). The LPC failed to 
upregulate COX-2 mRNA when applied in combination 
with an equimolar amount of NEFA-free BSA (50 µM 
NEFA-free BSA + 50 µM LPC). When, based on the as-
sumption that 1 mol of BSA binds 5 mol of LPC ( 43 ), 
the BSA concentration was adjusted to yield roughly 10 
µM of free LPC (8.8 µM NEFA-free BSA + 50 µM LPC), 
the upregulation of COX-2 mRNA could be restored 
( Fig. 2B ). 
 LPC-induced 6-keto PGF 1   production is mediated 
by COX 
 LPC upregulates COX-2 mRNA but not COX-2 pro-
tein.  The ability of both specifi c COX-1 (SC-560; 100 
nM) and COX-2 (NS-398; 20 µM) inhibitors to prevent 
the LPC-mediated increase of 6-keto PGF 1   clearly dem-
onstrated the involvement of both COX-enzymes ( Fig. 
2A ). To further characterize the involvement of COX 
enzymes COX-1 and COX-2, mRNA and protein abun-
dance, respectively, were monitored in LPC-treated 
HAEC. COX-1 mRNA was unaltered by LPC (supple-
mentary Fig. IIA). COX-2 mRNA was induced 3-fold by 
 Fig.  1. Basal production of prostanoids and LPC-elicited 6-keto PGF 1   production in HAEC. HAEC were 
treated with 10 µM LPC (B) or solvent (PBS) (A) in serum-free medium for 5 h. Cell culture supernatants 
were subjected to prostanoid profi ling by GC-MS/MS (A) or EIA for quantifi cation of 6-keto PGF 1   (B). Re-
sults are means ± SEM of two (A) and fi ve (B) experiments performed in duplicate. HAEC, human aortic 
endothelial cell; LPC, lysophosphatidylcholine. 
 Fig.  2. Involvement of COX isoforms and the impact of LPC on COX-2 mRNA and COX-2 protein expres-
sion in HAEC. A: HAEC were preincubated with isotype-specifi c COX inhibitors (COX-1; SC-560), (COX-2; 
NS-398), or vehicle (DMSO) for 30 min before their exposure to 10 µM LPC in serum free medium for 5 h. 
6-keto PGF 1   concentration in cell culture supernatants was determined by EIA. Results shown are mean ± 
SEM of one representative experiment (n = 3). B: For determination of COX mRNA levels, HAEC were incu-
bated either with 10 µM LPC, 50 µM LPC + 50 µM BSA (equimolar) or 50 µM LPC + 8.8 µM BSA (  10 µM free 
LPC) for 1 h. Subsequently, RNA was isolated and the relative COX-2 mRNA abundance was determined by 
qRT-PCR as described in “Materials and Methods.” Results shown are mean ± SEM of one representative experi-
ment (n = 3). C: After 5 h of incubation with 10 µM LPC, HAEC COX-2 protein content was determined by 
10% SDS-PAGE followed by immunoblotting using COX-2 and actin antibodies. Bands were visualized using 
appropriate secondary antibodies and an ECL substrate. A representative Western blot out of three is shown. 
COX, cyclooxygenase; HAEC, human aortic endothelial cell; LPC, lysophosphatidylcholine. 
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(PLC) inhibitor, and 2-APB, an inositol-3 phosphate (IP 3 ) 
receptor antagonist, completely blocked the increase in 
[Ca 2+ ] i elicited with all tested LPC ( Fig. 4C and supple-
mentary Fig. IIIA, B). From these results, we concluded 
that LPC-elicited increase in [Ca 2+ ] i is partially due to IP 3 -
triggered Ca 2+ release from endoplasmatic reticulum (ER) 
and infl ux of extracellular Ca 2+ . Additionally, these fi nd-
ings strongly suggest that the capacity of LPC to promote 
cPLA2-dependent AA release is related to its capacity to 
increase [Ca 2+ ] i . 
 Conversion of AA to 6-keto PGF 1   is not compromised by 16:0 
LPC.  The fi ndings presented in  Figs. 1 and 3 clearly 
showed that the capacity of 16:0 LPC to induce cPLA2-
mediated AA release is unrelated to its capacity to elicit 6-keto 
PGF 1   production. Therefore, we examined whether 16:0 
LPC compromises the conversion of AA to 6-keto PGF 1   . As 
shown in  Fig. 5A , the production of 6-keto PGF 1   elicited by 
exogenous AA was unaltered by 16:0 LPC. The conversion 
of AA released (from cellular phospholipids) upon A23187 
treatment to 6-keto PGF 1   was even promoted by 16:0 LPC 
( Fig. 5A ). Hence, the utilization of neither exogenous nor 
endogenous AA is compromised by 16:0 LPC. 
 Magnitude of 20:4 LPC-elicited 6-keto PGF 1   production is 
similar to that of AA.  To explain the pronounced capabil-
ity of 20:4 LPC to elicit 6-keto PGF 1   production despite its 
moderate capacity to promote AA release, we compared 
the magnitude of 6-keto PGF 1   induction elicited by 20:4 
LPC with that of AA. As shown in  Fig. 5B , cells incubated 
with 20:4 LPC (10 µM) secreted 6-keto PGF 1   with similar 
kinetics and effi ciency as cells incubated with AA (10 µM), 
suggesting that 20:4 LPC might serve as a donor of AA for 
6-keto PGF 1   production. 
 20:4 LPC is a weak inducer of endogenous 6-keto PGF 1   
production.  To examine the capacity of 20:4 LPC to 
 However, like COX-1 (supplementary Fig. IIB), COX-2 
protein was not increased after a 5 h incubation with LPC 
as determined by Western blotting ( Fig. 2C ), leading us to 
the conclusion that COX protein upregulation could not 
account for the LPC-mediated increase of 6-keto PGF 1   . 
 LPC promote cPLA2-dependent AA release in HAEC.  To 
elucidate the underlying mechanism for LPC-elicited 
6-keto PGF 1   production, we examined the role and con-
tribution of cPLA2, the major PLA2 implicated in the gen-
eration of AA for PG synthesis. As shown in  Fig. 3A , a 
specifi c cPLA2 inhibitor (see “Materials and Methods”; 1 
µM) effi ciently decreased the LPC-elicited 6-keto PGF 1   
production in HAEC, strongly indicating a role for cPLA2. 
To further examine the impact of LPC on cPLA2,  14 C-AA 
release was determined in HAEC. As shown in  Fig. 3B , the 
highest (4.5-fold) induction of  14 C-AA release was obtained 
with 16:0 LPC and was less pronounced (2- and 2.7-fold) 
with LPC 18:1 and 20:4, respectively. The effects of all LPC 
could be decreased by preincubation with the specifi c 
cPLA2-inhibitor ( Fig. 3B ), which also effi ciently decreased 
A23187-induced  14 C-AA release and 6-keto PGF 1   produc-
tion in HAEC (not shown). As cPLA2 activation is postu-
lated to be dependent on a transient increase in cytosolic 
calcium concentration [Ca 2+ ] i , we tested the ability of the 
LPC to modulate [Ca 2+ ] i . 
 LPC increase [Ca 2+ ] i .  In contrast to a marked increase 
in [Ca 2+ ] i by 16:0 LPC, a less pronounced but sustained 
increase was evoked by LPC 18:1 and 20:4 in the presence 
of extracellular Ca 2+ ( Fig. 4A ). In the absence of extracel-
lular Ca 2+ (EGTA), the increase in [Ca 2+ ] i triggered by 16:0 
LPC was low and similar to that of 18:1 and 20:4, respec-
tively ( Fig. 4B ). Furthermore, EGTA did not alter the mag-
nitude of the initial [Ca 2+ ] i peak elicited by 18:1 and 20:4 
LPC; however, it rendered the signal transient ( Fig. 4B ). 
Under EGTA-conditions, both U73122, a phospholipase C 
 Fig.  3. Role of cPLA2 in LPC-elicited 6-keto PGF 1   production and impact of LPC on cPLA2-mediated AA 
release. A: HAEC were preincubated with a specifi c cPLA2 inhibitor or vehicle (DMSO) for 30 min before ex-
posure to 10 µM LPC in serum-free medium for 5 h. 6-keto PGF 1   in cell culture supernatants was quantifi ed 
by EIA. Results are mean ± SEM of seven separate experiments. B: HAEC were labeled with  14 C-AA for 20 h. 
After preincubation with cPLA2 inhibitor or vehicle (DMSO) for 30 min, cells were exposed to serum-free 
medium supplemented with 50 µM LPC + 3.7 µM BSA in the presence or absence of cPLA2 inhibitor for 20 
min. Lipid extracts of cell media were separated by TLC and analyzed by densitometric quantifi cation of  14 C-AA 
spots. The amount of  14 C-AA released into medium was normalized to total cellular radioactivity measured by 
scintillation counting of cell lysates (AU). Results are mean ± SEM of three experiments. AA, arachidonic acid; 
HAEC, human aortic endothelial cell; LPC, lysophosphatidylcholine; cPLA2, cytosolic phospholipase A2. 
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21, 22 ), unsaturated LPC (18:1, 18:2, and 20:4) has not 
been studied so far. Therefore, we examined the capability 
of those unsaturated LPC species, along with established 
16:0 LPC, to modulate PGI 2 production in HAEC and in 
mice. 
 As found by MS analysis of cell media, HAEC produce 
PGI 2 , TXA 2 , PGF 2   , and PGE 2 . Considering the fact that 
HAEC, like human coronary artery endothelial cells 
(HCAEC) ( 44 ), express PGI 2 synthase (PGIS), PGE 2 syn-
thase (mPGES-1), and thromboxane synthase (TBXS) (not 
shown), it is conceivable that those prostanoids are prod-
ucts of enzymatic transformation of PGH 2 . However, we 
cannot completely exclude the possibility that a portion of 
the secreted prostanoids is generated by spontaneous, non-
enzymatic transformation of PGH 2 ( 45 ). 
 In the present study, we found remarkable acyl-chain-
dependent differences in the capability of LPC species to 
augment endothelial production of PGI 2 measured as sta-
ble degradation product 6-keto PGF 1   . In contrast to LPC 
18:1 and 20:4, which were much more potent inducers of 
6-keto PGF 1   than 16:0 LPC, LPC 18:2 was completely inca-
pable of altering 6-keto PGF 1   production in HAEC. The 
observed 6-keto PGF 1   stimulation was sensitive to both 
COX-1- and COX-2-specifi c inhibitors, indicating that in 
HAEC exposed to LPC both COX enzymes are function-
ally coupled to PGIS ( 37 ). In line with a previous fi nding 
( 21 ) describing the impact of 16:0 LPC on COX-2 expres-
sion in human umbilical vein endothelial cells (HUVEC), 
our LPC increased COX-2 mRNA without altering COX-1 
mRNA. In contrast to our fi ndings, Zembowicz et al. ( 21 ) 
induce 6-keto PGF 1   production from endogenous cellu-
lar AA and to compare it with that of 16:0 LPC, we deter-
mined  14 C-6-keto PGF 1   secretion from  
14 C-labeled HAEC 
exposed to respective LPC. As shown in  Fig. 5C, the 20:4 
LPC-elicited  14 C-6-keto PGF 1   production was markedly 
lower compared with 16:0 LPC, clearly showing the minor 
contribution of endogenous AA to the 20:4 LPC-elicited 
6-keto PGF 1   production. This fi nding further corrobo-
rated the role of 20:4 LPC as a donor of AA. 
 LPC augment PGI 2 production in mice.  Finally, we tested 
the ability of LPC to promote the production of 6-keto 
PGF 1   in vivo. For this purpose, LPC was injected into the 
tail vein of fasted C57Bl/6J mice. The dose of injected LPC 
was 20 mg/kg to achieve plasma concentrations of approx-
imately 10 µM of free LPC, after saturation of LPC binding 
sites of albumin and other plasma proteins. In accordance 
with in vitro data, 16:0, 18:1, and 20:4 LPC induced 6-keto 
PGF 1   formation in vivo ( Fig. 6 ), however, with a slightly 
different order of potency as found in HAEC. 
 DISCUSSION 
 Identifi cation of LPC 16:0, 18:1, 18:2, and 20:4 as major 
LPC species generated by the action of EL on HDL ( 40 ) 
prompted us to examine their impact on endothelial pros-
tanoid production with the focus on PGI 2 . Whereas three 
studies provided evidence to support the role for 16:0 LPC 
as a modulator of endothelial prostanoid production ( 14, 
 Fig.  4. Impact of LPC on cytosolic calcium concentration [Ca 2+ ] i . Fura-2/AM-loaded HAEC were tryp-
sinized and resuspended either in Ca 2+ -containing buffer (A) or Ca 2+ -free buffer containing EGTA (B and C). 
The ratio of fura-2 fl uorescence intensity at the two excitation wavelengths (340/380 ratio) was monitored 
spectrophotometrically in a stirring cuvette during exposure to 10 µM LPC. In (C), cells were preincubated 
without or with 2-APB or U73122 (U73) for 2 and 5 min, respectively, before application of 18:1 LPC. Results 
are representative single traces out of three experiments performed in duplicate. HAEC, human aortic en-
dothelial cell; LPC, lysophosphatidylcholine. 
 at Terkko - N
ational Library of Health Sciences, on M
ay 16, 2016
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2010/07/07/jlr.M006536.DC1
Supplemental Material can be found at:
Lysophosphatidylcholine and prostacyclin production 2963
cPLA2 are used rather for reacylation of 16:0 LPC than as 
substrate for COX enzymes. Additionally, 16:0 LPC might 
interfere with functional coupling between cPLA2 and 
COX enzymes, which is a prerequisite for effi cient supply 
of AA released by cPLA2 to COX enzymes ( 37 ), or alterna-
tively, it might attenuate the activity of PGIS, resulting in 
reduced conversion of released AA to PGI 2 . However, all 
these possibilities seem not to apply in our experimental 
and Rikitake et al. ( 22 ) demonstrated an increase in 
COX-2 protein upon exposure of HUVEC and bovine aor-
tic endothelial cells (BAEC) to 16:0 LPC. The lack of 
COX-2 protein upregulation in our experimental model 
might be due to a lower responsiveness of HAEC in con-
trast to HUVEC and BAEC to LPC in terms of COX-2 in-
duction. Additionally or alternatively, the amount and the 
form in which LPC is applied, namely 100 µM LPC in the 
presence of 5% FCS ( 21 ) or 20 µM LPC ( 22 ) versus 10 µM 
LPC in serum-free medium in our experimental system, 
might explain the discrepancy between our fi ndings and 
those of others. Our fi ndings provide clear evidence that 
the basal expression of COX-2 is suffi cient to accomplish 
LPC-elicited 6-keto PGF 1   production in HAEC. This is in 
line with the crucial role of basal endothelial COX-2 ex-
pression for the maintenance of vascular health, exempli-
fi ed by cardiovascular events upon the inhibition of COX-2 
by “coxibs” ( 46–48 ). 
 Strikingly, 16:0 LPC compared with 18:1 and 20:4 LPC 
was the least potent inducer of 6-keto PGF 1   , whereas it 
was the most potent promoter of [Ca 2+ ] i increase and of 
cPLA2-mediated AA release. The profound activation of 
cPLA2 and concomitant AA release were also reported for 
16:0 LPC in HUVEC; however, this study unfortunately 
did not address the impact of LPC on 6-keto PGF 1   pro-
duction ( 14 ). From our fi ndings, it appears that 16:0 LPC 
promotes AA release but reduces its full utilization toward 
the production of 6-keto PGF 1   . As 16:0 LPC is effi ciently 
converted to PC after uptake into cells ( 12 ), it is conceiv-
able that substantial amounts of AA released by activated 
 Fig.  5. Impact of LPC on exogenous and endogenous AA utilization for 6-keto PGF1   synthesis. A: HAEC were exposed to 10 µM 16:0 LPC 
or PBS in the presence of either 10 µM AA for 5 h or in the presence of 0.5 µM A23187 for 20 min. 6-keto PGF 1   in cell culture supernatants 
was quantifi ed by EIA. Results are mean ± SEM of three separate experiments. B: HAEC were treated with either 10 µM AA or 10 µM 20:4 
LPC and 6-keto PGF 1   in cell culture supernatants. was quantifi ed by EIA at the indicated time points. Results are mean ± SEM of 3 separate 
experiments. C:  14 C-AA labeled HAEC were exposed to PBS or LPC for 5 h, followed by TLC separation of cell media lipids and densito-
metric quantifi cation of  14 C-spots comigrating with 6-keto PGF 1   . Results are mean ± SEM of three separate experiments. AA, arachidonic 
acid; HAEC, human aortic endothelial cell; LPC, lysophosphatidylcholine. 
 Fig.  6. Effect of LPC on 6-keto PGF 1   production in mouse plasma. 
Following a 6 h fasting period, 4–7 mice per group were injected via 
tail vein with either 20 mg/kg LPC in a total volume of 100 µl 0.9% 
NaCl or 0.9% NaCl alone. After 20 h, blood was collected from the 
retro-orbital plexus into tubes containing indomethacin and EDTA, 
followed by immediate centrifugation for the determination of 
6-keto PGF 1   in plasma. Results represent two experiments, whiskers 
indicate the range from MIN to MAX. AA, arachidonic acid; LPC, 
lysophosphatidylcholine. 
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channels independent of ER-empting ( 53 ), as well as by 
promoting membrane hyperpolarization due to the open-
ing of Ca 2+ -activated K + channels ( 54 ). Future studies 
should clarify the difference in the capability of the tested 
LPC species to elicit an increase in [Ca 2+ ] i and to identify 
the routes of Ca 2+ in HAEC. 
 To demonstrate the physiologic relevance of our fi nd-
ings, we injected LPC intravenously into mice. The amount 
of injected LPC was chosen to yield approximately 5–10 
µM of free LPC, assuming scavenging by albumin and 
other carrier plasma proteins like   -1-acid glycoprotein 
(AGP) ( 9 ). Several studies have shown that the presence 
of albumin profoundly infl uences the bioactivity of LPC 
( 41, 55–57 ), clearly pointing to the requirement for the 
free, nonprotein-bound LPC. In accordance with those 
fi ndings was the inability of LPC to upregulate COX-2 
mRNA when applied along with equimolar amounts of 
BSA and restoration of LPC-elicited COX-2 mRNA upreg-
ulation when BSA concentration was adjusted to yield ap-
proximately 10 µM of free LPC ( Fig. 2B ). All LPC species 
elicited 6-keto PGF 1   production in mice, clearly arguing 
for their role in PGI 2 production in vivo. The order of po-
tency was slightly different compared with HAEC, with the 
less pronounced effect of 18:1 LPC compared with 16:0 
and 20:4 LPC. This discrepancy might be due to differ-
ences in metabolic and pharmacokinetic properties of 
18:1 LPC compared with 16:0 and 20:4, like half-life in 
plasma, clearance by the liver, or scavenging by albumin, 
resulting in lower bioavailability and consequently dimin-
ished ability to promote 6-keto PGF 1   production in vivo. 
Of note, preliminary monitoring of 6-keto PGF 1   in mice 
showed a pronounced dissipation in basal plasma levels in 
untreated mice, explaining the variance observed in ex-
perimental groups upon LPC treatment. 
 Under physiological conditions, plasma albumin scav-
enges LPC, thus blunting its action on the vascular endo-
thelium. However, it is very likely that under infl ammatory 
conditions when EL ( 58, 59 ) and other serum phospholi-
pases ( 1, 2, 60 ) are upregulated, the excessive lipolysis in 
the plasma compartment raises the concentrations of FAs 
and LPC, leading to saturation of LPC binding sites on al-
bumin and other plasma proteins and allowing the action 
of free LPC on vascular endothelium. The direct conse-
quence of the action of LPC on vascular endothelium 
might be vasoprotective due to promotion of PGI 2 produc-
tion. However, as the expression of PGE 2 , TxA 2 , and PGF 2   
might also be altered by LPC in a similar manner as PGI 2 , 
further experiments are required to examine the impact 
of LPC on those prostanoids with opposite impact on vas-
cular function. 
 To our knowledge, this is the fi rst study addressing the 
impact of the acyl-chain length and degree of saturation 
on the capacity of LPC to augment the formation of en-
dothelial 6-keto PGF 1   . Here we show that the magnitude 
of increase in LPC-elicited 6-keto PGF 1   and the relative 
contribution of underlying mechanisms, including in-
crease in [Ca 2+ ] i and cPLA2 activation as well as provision 
of exogenous substrate, are strongly related to acyl-chain 
length and degree of saturation.  
system, as experiments addressing a possible inhibitory ef-
fect of 16:0 LPC ( Fig. 5A ) on the conversion of either ex-
ogenous or endogenous AA to 6-keto PGF 1   production 
failed to provide evidence for an inhibitory effect of 16:0 
LPC. In HAEC, 16:0 LPC even augmented A23187-induced 
6-keto PGF 1   production. A very weak 6-keto PGF 1   re-
sponse to 16:0 LPC, despite COX-2 upregulation, was also 
found in HUVEC ( 21 ). Further experiments are required 
to clarify the failure of 16:0 LPC to induce a more effi cient 
6-keto PGF 1   production. 
 20:4 LPC was the most potent inducer of 6-keto PGF 1   
formation, whereas it was in the same range as 18:1 LPC 
regarding induction of [Ca 2+ ] i and cPLA2-mediated AA 
release. Accordingly, the induction of cPLA2-mediated 
AA release could not explain the marked 8.3-fold in-
crease in 6-keto PGF 1   elicited with 20:4 LPC. Because 
the rate of 6-keto PGF 1   production elicited by 20:4 LPC 
was similar to that of AA, it is likely that 20:4 LPC serves 
as a source of AA for COX enzymes. This, in our opinion, 
makes the major contribution to the marked increase in 
20:4 LPC-elicited 6-keto PGF 1   production. Beside differ-
ent cellular lysophospholipases, cPLA2 may by its lyso-
phospholipase activity ( 49 ) accomplish the release of AA 
from 20:4 LPC. Indeed, 20:4 LPC-elicited 6-keto PGF 1   
production was signifi cantly decreased by cPLA2 inhibi-
tor ( Fig. 3A ), which probably refl ected the inhibition of 
both cPLA2 activities, the phospholipase activity involved 
in liberation of AA from cellular phospholipids and the 
lysophospholipase activity responsible for deacylation of 
20:4 LPC. Importantly, the most potent inducer of 6-keto 
PGF 1   production among tested LPC, the 20:4 LPC, was a 
much weaker inducer of 6-keto PGF 1   production from 
endogenous AA than 16:0 LPC ( Fig. 5C ). These fi ndings 
corroborate further the role of 20:4 LPC as a provider of 
exogenous AA. We are aware that our conclusions re-
garding the role of 20:4 LPC as a source of AA are based 
on indirect experimental approaches, but the lack of a 
commercially available 20:4 LPC labeled in the AA moi-
ety precludes the possibility of directly demonstrating 
the conversion of 20:4 LPC-derived AA to labeled 6-keto 
PGF 1   . 
 Regarding 18:2 LPC, we speculate that its failure to pro-
mote 6-keto PGF 1   production might be due to a negligi-
ble impact on cPLA2-mediated AA release and inability to 
act as a substrate provider for COX enzymes like 20:4 LPC. 
Indeed, 18:2 FA is a poor substrate for the elongation/
desaturation machinery in endothelial cells ( 50, 51 ). 
 A transient increase in [Ca 2+ ] i is required for the trans-
location of cPLA2 from cytosol to the cellular membrane 
surface ( 52 ). In line with this, we found that the extent 
of LPC-mediated AA release was fully related to the LPC-
elicited increase in [Ca 2+ ] i. . All tested LPC generated a bi-
phasic increase in [Ca 2+ ] i with a rapid, IP 3 -triggered initial 
increase caused by the release of Ca 2+ from intracellular 
stores, which was similar for all LPC, followed by sustained 
infl ux of extracellular Ca 2+ , which is strongly induced by 
16:0 LPC and only slightly by 18:1 and 20:4 LPC. 16:0 LPC 
has been shown to promote the transmembrane Ca 2+ in-
fl ux in endothelial cells by opening store-operated Ca 2+ 
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 ERRATA 
 The authors of  “ Acyl chain-dependent effect of lysophosphatidylcholine on endothelial prostacyclin production ” 
(  J. Lipid Res . 51:  2957 – 2966 ) have advised the journal that two authors were inadvertently omitted from the original list 
of authors. 
 The author list that initially appeared online and in print was as follows: 
 Monika Riederer, Pauli J. Ojala, Andelko Hrzenjak, Michaela Tritscher, Martin Hermansson, Bernhard Watzer, Horst 
Schweer, Gernot Desoye, Akos Heinemann, and Sasa Frank 
 The author list should have read: 
 Monika Riederer, Pauli J. Ojala, Andelko Hrzenjak,  Wolfgang F. Graier, Roland Malli , Michaela Tritscher, Martin 
Hermansson, Bernhard Watzer, Horst Schweer, Gernot Desoye, Akos Heinemann, and Sasa Frank 
Additionally, corrections were needed to the authors’ affi liations. 
The original affi liations appeared in print as follows:
Institute of Molecular Biology and Biochemistry,* Center of Molecular Medicine; Finnish Red Cross Blood
Service; † Division of Pulmonology, §  Department of Internal Medicine; Department of Biochemistry,**
Institute of Biomedicine, University of Helsinki, Helsinki, Finland; Department of Pediatrics, ††  Philipps
University of Marburg, Marburg, Germany; and Clinic of Obstetrics and Gynecology; §§  Institute of
Experimental and Clinical Pharmacology,*** and Institute of Molecular Biology & Biochemistry, ††† 
Center of Molecular Medicine, Medical University of Graz, Graz, Austria
The affi liations should have read:
Institute of Molecular Biology and Biochemistry,* Center of Molecular Medicine, Medical University of
Graz, Graz, Austria; Finnish Red Cross Blood Service, †  Helsinki, Finland; Division of Pulmonology, § 
Department of Internal Medicine, Medical University of Graz, Graz, Austria; Department of Biochemistry,**
Institute of Biomedicine, University of Helsinki, Helsinki, Finland; Department of Pediatrics, ††  Philipps
University of Marburg, Marburg, Germany; and Clinic of Obstetrics and Gynecology; §§  and Institute of
Experimental and Clinical Pharmacology,*** Center of Molecular Medicine, Medical University of Graz,
Graz, Austria
 The incorrect author list and affi liations initially appeared online but have since been corrected in the article and the 
table of contents. 
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